Thursday 16 October, 2025
Objectives: To develop a population pharmacokinetic-pharmacodynamic (PK-PD) model describing the concentration-effect relationships for morphine on experimental pain caused by skin…
Read morePoster: CNS
Effect of Carbamazepine Daily Dose on Topiramate Clearance – Population Modelling Approach
Thursday 16 October, 2025
Objectives: The aim of the study was to investigate influence of carbamazepine (CBZ) on topiramate (TPM) oral clearance (CL/F) in…
Read moreModeling & simulation of ONO-4641, a sphingosine 1-phosphate receptor modulator, to support dose selection with phase 1 data
Thursday 16 October, 2025
Objectives: ONO-4641 is an orally administered sphingosine 1-phosphate (S1P) receptor modulator that is currently under clinical evaluation for multiple sclerosis…
Read moreQuantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, using Mouse EEG Data
Thursday 16 October, 2025
Objectives: AZD6765 and ketamine are NMDA channel blockers, which differ in how they interact with the NMDA channel. Ketamine has…
Read morePopulation PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels in vivo.
Thursday 16 October, 2025
Objectives: The transmembrane aspartic acid protease BACE1 cleaves amyloid precursor protein (APP) to generate soluble APPβ. The remainder of APP…
Read morePrediction of Serotonin 2A Receptor (5-HT2AR) Occupancy in Man From Nonclinical Pharmacology Data. Exposure vs. 5-HT2AR Occupancy Modeling Used to Help Design a Positron Emission Tomography (PET) Study in Healthy Male Subjects.
Thursday 16 October, 2025
Objectives: JNJ-mGluR2 PAM, a positive allosteric modulator of the metabotropic glutamate receptor-2 and 5-HT2AR antagonist, is currently in development for…
Read morePopulation pharmacokinetic analysis of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia
Thursday 16 October, 2025
Objectives: A population PK model of JNJ-37822681 was developed with the aim to describe the PK of JNJ-37822681 in healthy…
Read morePopulation Pharmacokinetics of Risperidone and 9-hydroxy-risperidone in psychiatric patients.
Thursday 16 October, 2025
Objectives: A therapeutic range has been proposed for risperidone (RISP) and 9-hydroxy-risperidone (9OHRISP). Their pharmacokinetics is subject to a high…
Read moreA Mixed-Effects Markov Model for Characterizing the Time Course of the Transitions between Different Extrapyramidal Side Effects Severity Levels
Thursday 16 October, 2025
Objectives: Extrapyramidal side effects (EPS) associated with antipsychotic drug administration are often spontaneously reported by patients and graded by clinicians…
Read morePopulation pharmacokinetic and pharmacodynamic analysis of cortisol in serum and saliva in healthy male volunteers after an acute 5-hydroxytryptophan (5-HTP) challenge test
Thursday 16 October, 2025
Objectives: Serum cortisol is a frequently used neuroendocrine endpoint of the 5-HTP challenge test, which quantifies central serotonergic neurotransmission. Sampling…
Read more